The Metabolic Stack

Why These Two Compounds Together

Most fat loss approaches work on one pathway. The Metabolic Stack works on two that don’t overlap — which is exactly why practitioners combine them.

Semaglutide addresses appetite and caloric intake. It mimics a gut hormone that signals fullness, slows digestion, and reduces the constant pull toward food. For most people who struggle with weight, appetite dysregulation is the primary barrier. Semaglutide removes that barrier directly.

AOD-9604 targets fat cells directly. It’s a modified fragment of human growth hormone — specifically the 16 amino acids responsible for fat metabolism, isolated from the parts that cause growth and blood sugar disruption. In theory, it stimulates lipolysis (fat breakdown) and inhibits lipogenesis (new fat storage) at the cellular level.

The combination logic: semaglutide reduces how much energy goes in. AOD-9604 encourages the body to preferentially use stored fat as that energy. Two mechanisms, one goal, neither competing with the other.

🔍  EVIDENCE NOTE  Before you invest in this stack, read the evidence section. Semaglutide has Grade A evidence — one of the most rigorously studied weight loss medicines available. AOD-9604 has Grade D evidence and its Phase 2b clinical trial (n=300) failed to show statistical significance for weight loss. The combination has no clinical trial data at all. The rationale is mechanistically sound; the human evidence for AOD-9604’s contribution is not.

What Each Compound Does

Semaglutide — the primary driver

GLP-1 receptor agonist. Modified version of a gut hormone your body naturally produces, engineered to last a full week instead of minutes. Activates receptors in the brain that reduce appetite, slows gastric emptying, and improves blood sugar handling. The active ingredient in Ozempic and Wegovy.

TGA Status	Schedule 4 (S4 POM) — Prescription Only Medicine. TGA-approved. Any GP can prescribe.
WADA Status	Not Prohibited. No TUE required for competitive athletes.
Evidence	Grade A. ~45,000+ human subjects. STEP 1 trial: ~15% average body weight loss at 68 weeks.
Primary role	Appetite suppression and caloric reduction — the dominant mechanism in this stack.
Cost	$150–900 AUD/month depending on PBS eligibility and whether compounded or brand-name.

AOD-9604 — the supporting compound

Modified fragment of human growth hormone (amino acids 177–191). Proposed mechanism: stimulates beta-3 adrenergic receptors to trigger lipolysis and inhibit lipogenesis — fat breakdown without the growth-promoting or blood sugar effects of full HGH. Developed in Australia by Metabolic Pharmaceuticals.

TGA Status	Not scheduled — research chemical. Not TGA-approved as a medicine.
WADA Status	Not Prohibited. Not on the WADA 2025 Prohibited List.
Evidence	Grade D. ~300 human subjects. Phase 2b trial (2007) failed primary endpoint for statistical significance in weight loss.
Primary role	Direct fat metabolism support — theoretical complement to semaglutide’s appetite mechanism.
Cost	$80–200 AUD/month via research peptide suppliers or compounding pharmacy.

✅  FACT-CHECK  Semaglutide data: Wilding et al. (2021) STEP 1, NEJM [REF:1]; FDA/TGA approved prescribing information [REF:3]. AOD-9604 data: Heffernan et al. (2001) Obes Res; Metabolic Pharmaceuticals Phase 2b trial (2007, n=300). TGA and WADA status verified 24/02/2026.

The Protocol — Week by Week

Phase 1: Foundation (Weeks 1–8)

Start semaglutide alone. Do not add AOD-9604 in the first phase. You need to establish your semaglutide tolerance and complete initial titration before adding a second compound.

Semaglutide Week 1–4	0.25mg SubQ once weekly. Appetite suppression will be mild. GI side effects (nausea, loose stools) are common — this is expected and usually improves. Eat smaller meals. Avoid high-fat foods during this phase.
Semaglutide Week 5–8	Increase to 0.5mg once weekly. Measurable appetite reduction should be established by now. Weight loss of 2–4kg is typical by end of Week 8.
AOD-9604 Phase 1	Not started yet. Wait until semaglutide is tolerated before adding AOD-9604.
Lifestyle requirements	Caloric deficit (semaglutide makes this physiologically easier). Minimum 3x resistance training per week to preserve lean muscle. Protein intake: ≥1.2g per kg of bodyweight daily. Hydration is critical — GI sides dehydrate you.

Phase 2: Stack Active (Weeks 9–16)

Semaglutide is now established and tolerated. Add AOD-9604 and continue titrating semaglutide toward maintenance dose.

Semaglutide Week 9–12	Increase to 1mg once weekly if 0.5mg is tolerated. Some practitioners hold at 0.5mg if results are adequate — there is no clinical requirement to reach maximum dose.
Semaglutide Week 13–16	Continue titrating: 1mg → 1.7mg → 2.4mg weekly, increasing every 4 weeks based on tolerance and response.
AOD-9604	250–300mcg SubQ daily. Morning, fasted, is the standard timing — theoretical synergy with the body’s natural morning fat mobilisation window. Reconstitute with bacteriostatic water. Store refrigerated 2–8°C. Use within 14–21 days of reconstitution.
What to expect	Semaglutide is doing the heavy lifting on weight loss. AOD-9604’s contribution at this stage is modest and individual — some users report accelerated fat loss in stubborn areas; others notice minimal additional effect.

Phase 3: Maintenance Assessment (Weeks 17–24)

By week 16–20 you should be at or near maximum semaglutide dose. Assess results and decide whether to continue the full stack, maintain semaglutide alone, or discuss a sustainable long-term plan with your GP.

Semaglutide	Continue at maintenance dose (typically 1.7–2.4mg weekly). Do not stop abruptly — weight regain is rapid after discontinuation without a plan.
AOD-9604	Continue at 250–300mcg daily, or cycle off and reassess its contribution. Its short half-life (~15–30 minutes) means effects are immediate-onset and reverse quickly when stopped.
Review point	At 16 weeks, review blood work (see monitoring section). Assess total body weight change, lean mass retention, and tolerance. Discuss with your prescribing practitioner before adjusting.
Stopping plan	Do not stop semaglutide without a plan. STEP 1 extension data shows ~2/3 of lost weight returns within 1 year of stopping. Discuss a maintenance strategy with your GP before reaching this decision point. [REF:1]

ℹ️  NOTE  This protocol timeline is a framework, not a prescription. Your GP will adjust based on your individual response, health status, and blood work results. The titration schedule for semaglutide in particular must follow your prescribing practitioner’s guidance.

✅  FACT-CHECK  Semaglutide titration schedule sourced from approved prescribing information [REF:3]. AOD-9604 dosing (250–300mcg/day) sourced from Metabolic Pharmaceuticals protocol data and practitioner consensus — no controlled trial data on optimal dosing in combination with semaglutide. Weight regain data: STEP 1 extension [REF:1].

What to Expect — Honest Outcomes

Set expectations around semaglutide, not AOD-9604. Semaglutide is the compound with robust clinical data. AOD-9604 may contribute; it may not make a measurable difference for you individually.

Week 1–2	Appetite reduction noticeable from semaglutide. Food noise decreases. GI side effects common — nausea, loose stools. Normal and expected.
Week 4–8	2–4kg weight loss typical. Energy may be lower (caloric restriction effect). AOD-9604 not yet started.
Week 8–12	Both compounds now active. Continued steady weight loss. Semaglutide carrying the primary load. Some users report faster changes in body composition at this stage.
Week 16–24	Approaching maximum effect. STEP 1 showed ~15% average total body weight loss at 68 weeks for semaglutide 2.4mg/week group. Combined with AOD-9604, individual results vary — the additional contribution of AOD-9604 has not been quantified in controlled trials.
After stopping	Weight regain is likely without a long-term maintenance plan. This is not a short course — results require sustained use.

🔍  EVIDENCE NOTE  AOD-9604’s Phase 2b clinical trial failed to show statistically significant weight loss in its primary endpoint (n=300, Metabolic Pharmaceuticals, 2007). The compound has not completed Phase 3 trials. Evidence Grade D. This does not mean it is ineffective for everyone — it means the controlled evidence is not there to predict outcomes reliably. If budget is a constraint, semaglutide alone has substantially stronger evidence for fat loss results.

Legal Status — What’s Legal, What’s Grey, What You Need

Semaglutide — TGA	Schedule 4 (S4 POM). Legal with prescription. Any GP can prescribe. PBS-listed for T2DM (Ozempic) and obesity (Wegovy from July 2024). Verified: TGA.gov.au, 24/02/2026.
Semaglutide — WADA	Not Prohibited. Competitive athletes may use without a TUE. Verified: wada-ama.org/prohibited-list, 24/02/2026.
AOD-9604 — TGA	Not scheduled — research chemical. Not TGA-approved as a medicine. Available through research peptide suppliers and some compounding pharmacies. Legal grey area.
AOD-9604 — WADA	Not Prohibited. Not on the WADA 2025 Prohibited List. Verified: wada-ama.org/prohibited-list, 24/02/2026.
Stack overall	WADA-permitted for both compounds. Semaglutide requires a prescription. AOD-9604 does not require a prescription but has no approved medical indication.

⚠️  IMPORTANT  You cannot legally obtain semaglutide without a valid Australian prescription from a registered GP or specialist. Do not source it through unverified channels — product quality cannot be confirmed and the legal risk sits with the buyer.

✅  FACT-CHECK  TGA scheduling confirmed against TGA Scheduling Secretariat. WADA status for both compounds confirmed against WADA Prohibited List 2025. All verified 24/02/2026.

Side Effects — Both Compounds

Semaglutide side effects

Nausea	20–44% of users. Most common in weeks 1–8. Usually improves. Eat smaller meals, avoid fatty food.
Diarrhoea	15–30%. Related to slowed gastric emptying. Hydration is important.
Vomiting	8–24%. More common at higher doses. Slow titration reduces this significantly.
Constipation	10–24%. Persistent for some users.
Headache	14%. Often linked to reduced caloric intake in early weeks.
Serious risk	Thyroid C-cell tumour boxed warning (rodent studies — no confirmed human signal at 6+ years post-market). Contraindicated in MEN2/MTC history. Pancreatitis: rare but serious.

AOD-9604 side effects

Common	Injection site irritation, mild sting. Headache (reported in some users). Limited safety data from human trials.
Serious risk	Low concern — the fragment does not promote cell growth or disrupt hormonal feedback. However, limited long-term human safety data exists. Evidence Grade D.
Interactions	No significant known interactions with semaglutide. Do not combine semaglutide with other GLP-1 agonists (Tirzepatide, Retatrutide) — this is a semaglutide-specific contraindication, not AOD-9604.

✅  FACT-CHECK  Semaglutide side effect frequencies sourced from Wilding et al. (2021) STEP 1 [REF:1] and approved prescribing information [REF:3]. AOD-9604 side effect data sourced from Metabolic Pharmaceuticals Phase 2b trial (2007) and limited published case data — safety database is small.

Blood Work to Monitor

Baseline before starting. Review at 8 weeks and 16 weeks minimum.

• HbA1c and fasting glucose — blood sugar management markers
• Lipid panel — cardiovascular risk markers (semaglutide SELECT trial showed 20% CV event reduction)
• Pancreatic enzymes (lipase/amylase) — baseline and if abdominal pain develops
• Thyroid function — baseline given semaglutide boxed warning
• IGF-1 — confirm AOD-9604 is not causing IGF-1 elevation (the fragment should not, but verify)
• Kidney function — if pre-existing CKD
• Heart rate — semaglutide can modestly increase resting heart rate

Who This Protocol Is and Isn’t Right For

More likely to benefit

• Adults with BMI ≥30, or BMI ≥27 with a weight-related comorbidity, who have not achieved adequate results through diet and exercise alone
• People who want to address fat loss through two non-competing mechanisms simultaneously
• Those already planning to use semaglutide who want to explore whether AOD-9604 adds meaningful benefit for their specific goals
• Athletes in WADA-tested sports — both compounds are permitted (verify annually, WADA list updates January 1)

Not recommended for

• Personal or family history of MTC or MEN2 — semaglutide absolute contraindication
• Pregnancy or planned pregnancy within 2 months — Category X
• History of pancreatitis
• Anyone expecting significant results from AOD-9604 alone — the evidence does not support this
• Anyone seeking a short-term course — weight regain after stopping semaglutide is well-documented
• Under 18

Evidence Summary — The Honest Picture

Semaglutide evidence	Grade A. ~45,000+ human subjects. Multiple Phase 3 RCTs. FDA and TGA approved. Most rigorously studied weight loss medicine on this site. [REF:1] [REF:2]
AOD-9604 evidence	Grade D. ~300 human subjects. One Phase 2b trial — FAILED primary endpoint. No Phase 3 trials. No active clinical trials (0 as of 2025). Developed in Australia by Metabolic Pharmaceuticals. FDA GRAS status for food use — NOT approved as injectable therapeutic.
Combination evidence	Zero — no controlled trials of semaglutide + AOD-9604 in combination. The rationale is mechanistically plausible but unproven in humans.
Bottom line	This protocol is led by one of the most evidence-backed weight loss medicines in existence, supported by a research chemical with modest and unproven contribution. You are primarily paying for semaglutide’s results. AOD-9604 may add value. It may not. The evidence does not allow a confident answer.

🔍  EVIDENCE NOTE  AOD-9604 was developed in Australia specifically to provide fat loss benefits of HGH without its risks. The science made sense. The Phase 2b trial enrolled 300 participants and ran at multiple sites. It failed to show statistical significance for its primary weight loss endpoint. No further Phase 3 development occurred. This history belongs on every page that discusses AOD-9604 — most sites leave it out.

References

• [1] Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989-1002. DOI: 10.1056/NEJMoa2032183 (STEP 1 Trial — n=1,961)
• [2] Lincoff AM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med. 2023. DOI: 10.1056/NEJMoa2307563 (SELECT Trial — n=17,604)
• [3] FDA. Ozempic/Wegovy (semaglutide) Prescribing Information. Approval 2017/2021. fda.gov/drugs. TGA: tga.gov.au — Schedule 4 Prescription Only Medicine. Verified 24/02/2026.
• [4] Heffernan MA, et al. The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice. Endocrinology. 2001;142(12):5182-9.
• [5] Metabolic Pharmaceuticals. AOD-9604 Phase 2b Clinical Trial. n=300. Primary endpoint: weight loss. Result: failed to demonstrate statistical significance. 2007.
• [6] World Anti-Doping Agency. Prohibited List 2025. wada-ama.org/prohibited-list. Semaglutide: NOT listed. AOD-9604: NOT listed. Accessed 24/02/2026.
• [7] Therapeutic Goods Administration. Scheduling Secretariat. tga.gov.au. Semaglutide: S4 POM. AOD-9604: Not scheduled. Verified 24/02/2026.

Peptides Australia Editorial Team | Fact-checked: TGA Register + WADA 2025 Prohibited List | Last Reviewed: 24/02/2026

MEDICAL DISCLAIMER: This protocol is for informational purposes only and does not constitute medical advice. Semaglutide is a Schedule 4 Prescription Only Medicine under Australian TGA regulations. A valid prescription from a registered Australian medical practitioner is required for legal access. AOD-9604 is not TGA-approved. Consult your GP or a registered specialist before use.